Pinealon: Evidence and Research Limitations

What is Pinealon?

Pinealon is a name used for the tripeptide Glu-Asp-Arg, abbreviated EDR. It is discussed in the peptide-bioregulation literature. A short amino-acid sequence does not, by itself, establish brain delivery or tissue selectivity.

What the cited Review says

The review by Khavinson and colleagues, published online in December 2020, discusses EDR and possible regulation of gene expression and protein synthesis in the context of Alzheimer’s disease research. It draws on earlier cell and animal work and proposes molecular explanations. It is a review, not a new standalone animal experiment.

Our earlier reference to a foundational 2020 animal-model paper could not be verified and has been removed. The linked review is a different publication, used here for its actual scope rather than as a replacement proof of that claim.

Claims that remain Unestablished

This page previously inferred passive passage across the blood-brain barrier from molecular size. That inference was not supported by the cited sources. Brain exposure requires appropriate measurements; being small is not enough to establish it.

The review discusses proposed interactions with cellular components. It does not justify presenting selective delivery to brain tissue, direct DNA binding in people or clinical neuroprotection as established outcomes. Findings about other peptides or other tissues cannot establish those effects for EDR.

The broader programme reviews remain listed for context. They are not independent confirmation of every Pinealon-specific claim. The cited material does not establish a treatment recommendation or the safety of a supplied research material.

Published References

1. Khavinson V, Linkova N, Kozhevnikova E, et al. “EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease.” Molecules (Basel, Switzerland), 2020. PubMed
   A review of proposed EDR mechanisms, not the previously cited standalone animal study. Mechanistic proposals in a review are not independent experimental confirmation.
2. Khavinson VKh. “Peptides and Ageing.” Neuro endocrinology letters, 2002. PubMed
   Khavinson's programmatic overview paper outlining the bioregulator concept and its theoretical framework. Useful background for understanding what bioregulators are claimed to do and how the Russian programme thinks about peptide-based aging research.
3. Anisimov VN, Khavinson VKh. “Peptide bioregulation of aging: results and prospects.” Biogerontology, 2010. PubMed
   A broader review of the entire Khavinson bioregulator programme — useful context for understanding where Pinealon sits within the larger family of brain-, organ-, and tissue-specific bioregulator peptides developed over four decades.
4. Khavinson VKh, Tendler SM, Vanyushin BF, et al. “Peptide regulation of gene expression and protein synthesis in bronchial epithelium.” Lung, 2014. PubMed
   A mechanistic study on a different bioregulator (lung-targeting), but useful for understanding the gene-expression-regulation framework that Pinealon and other bioregulators are claimed to operate through. Same proposed mechanism, applied to a different tissue.

Browse all Pinealon research on PubMed →